Trial · NCT03696212
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
NCT03696212, Phase 1, Phase 2, Terminated, Arrys Therapeutics
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma. Trials, record NCT03696212. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03696212
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma
- NCT number
- NCT03696212
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 18 participants, actual
- Lead sponsor
- Arrys Therapeutics
- Conditions
- Non-small Cell Lung Cancer Adenocarcinoma
- Interventions
- grapiprant and pembrolizumab
- First posted
- 2018-10-04
- Last updated
- 2021-02-21
Source ClinicalTrials.gov
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Safety and tolerability of grapiprant in combination with pembrolizumab | Up to 90 days after the end of treatment (average of 7 months) | Number of incidence, severity, relationship, concomitant medications administered, and duration of treatment emergent adverse events using CTCAE v5.0 |
| Primary | Define the recommended phase 2 dose (RP2D) of grapiprant combined with pembrolizumab | Through Cycle 1 (21 days) | Number, incidence and severity of treatment related adverse events as assessed by CTCAE 5.0 |
| Primary | Objective response rate (ORR) | 7 months | Proportion of participants who achieved PR or better during the study per RECIST 1.1 and iRECIST |
| Secondary | Progression-free survival (PFS) | Up to 12 months | Participants who discontinue treatment without disease progression |
| Secondary | Overall survival (OS) | Up to 2 years from start of study drug | Date of study drug to date of death due to any cause |
| Secondary | Duration of treatment (DoT) | 7 months | Disease response for time of duration on treatment |
| Secondary | Disease control rate (DCR) | 7 months | Percentage of patients who have achieved CR, PR and stable disease |
| Secondary | Duration of response (DoR) | Up to 12 months | Time from documentation of tumor response to disease progression per RECIST and iRECIST 1.1 |
| Secondary | PK of grapiprant: AUC | Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with Cycle 4 (every 42 days) through end of treatment (average of 4 months). | Area under the plasma concentration-time curve |
| Secondary | PK of grapiprant: Cmax | Days 1 and 2 of first 2 cycles (every 21 days), followed by Day 1 of every even cycle beginning with Cycle 4 (every 42 days) through end of treatment (average of 4 months). | Peak serum concentration of grapiprant |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03696212
GET https://conductscience.org/api/trials/v1/NCT03696212/registered